Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

ther R&D expenses 579,926 552,146

-------------------------------------------------------------------------

Research and development expenses 2,125,811 3,218,237

-------------------------------------------------------------------------

-------------------------------------------------------------------------

For the first quarter of 2008, R&D decreased to $2,125,811 compared to $3,218,237 for the first quarter of 2007. The decrease in R&D was due to the following:

Manufacturing & Related Process Development ("M&P")

2008 2007

$ $

-------------------------------------------------------------------------

Product manufacturing expenses 467,328 1,748,417

Process development expenses 35,766 89,776

-------------------------------------------------------------------------

Manufacturing and related process development

expenses 503,094 1,838,193

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Our M&P expenses for the first quarter of 2008 decreased to $503,094 compared to $1,838,193 for the first quarter of 2007.

In the first quarter of 2008, our production activity decreased compared to the first quarter of 2007. During the first quarter of 2008, we entered into a contract to manufacture REOLYSIN(R) at the 40-litre scale. We commenced production under this contract towards the end of the first quarter of 2008. In the first quarter of 2007, along with a number of manufacturing runs at the 20-litre scale, we also incurred vial filling activity for the production runs that were complet
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  ArroGen Group, an integrated ... Fingerprint Molecular Identification™ (FMID) technology Aug. 2-8 at ... Sacramento, Calif. ... enable law enforcement agents, district attorneys and government ... suspects. By analyzing chemical residues on ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Nine field ... Iowa, Illinois and Indiana. Hosted by the Soil Health Partnership , the field ... lasting environmental benefits while potentially increasing farm productivity and income. , Brent Bible has ...
(Date:8/3/2015)... , Aug. 3, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... focused on the development of autologous cell therapies, announced today ... at the InvestMNT conference held in Minneapolis, Minnesota ... local time. Hall,s presentation will highlight RepliCel,s 18-month milestones including ... Europe , clinical data from both RCT-01 ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud to announce ... gluten in foods, has been accepted by AOAC International as Official First Action ... Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific monoclonal antibody ...
Breaking Biology Technology:ArroGen Previews New Fingerprint Molecular Identification Technology 2Soil Health Field Days Kick Off Throughout Midwest 2Soil Health Field Days Kick Off Throughout Midwest 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... TGH to Enhance Clinical Skills,Development, DENVER, Nov. ... partnership with the University of South Florida (USF) ... Health hospital,partners and for local and national health ... Center is located at Tampa,General Hospital, a major ...
... 10 NeurogesX, Inc.,(Nasdaq: NGSX ), a ... management therapies, announced today that,Anthony DiTonno, President and ... Rodman & Renshaw 10th Annual Healthcare Conference in ... DiTonno and Stephen Ghiglieri,Chief Financial Officer, will also ...
... Company Registered in Switzerland, Will Move its Headquarter ... Various Issues Related to Neovascularisation, - Gene Signal is Working ... Now in Phase III Trials, - Gene Signal Will Present ... the American Academy of Ophtalmologist in Atlanta, USA, the ...
Cached Biology Technology:Medical Simulation Corporation Announces Partnership With University of South Florida 2Medical Simulation Corporation Announces Partnership With University of South Florida 3NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference 2NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference 3Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection 2Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection 3
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
(Date:7/9/2015)... July 07, 2015 ... addition of the "Biometrics for Banking; Market ... report to their offering. The ... to this growth and the forecast is that ... revenue for companies involved in delivering biometric systems ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... attained very promising results on their initial investigations of a ... mass spectrometry of a single drop of blood serum, the ... of the patients tested. The results can be found online ... . "Because ovarian cancer is a disease of ...
... As much as 12 percent of the worlds human-caused greenhouse ... charcoal-like substance made from plants and other organic materials. Thats ... and materials were burned to generate energy, concludes a study ... calculations show that biochar can play a significant role in ...
... marine mosasaur Platecarpus , lived in the Cretaceous Period some ... an eel. That theory is debunked in a new paper published ... of scientists have reconceived the animal,s morphology, or body plan, based ... Los Angeles County. The paper was co-authored by ...
Cached Biology News:Initial trials on new ovarian cancer tests exhibit extremely high accuracy 2Charcoal takes some heat off global warming 2Charcoal takes some heat off global warming 3Charcoal takes some heat off global warming 4Charcoal takes some heat off global warming 5Mosasaur fossil at Natural History Museum of L.A. County re-explores 85-million-year-old sea monster 2
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis....
Loading Buffer...
Request Info...
Request Info...
Biology Products: